Level of S100B protein in blood plasma depends on the form of Parkinson's disease

The aim of the study is to investigate activity of markers of oxidative and nitrosative stresses in blood plasma of patients in the I–II stages of Parkinson’s disease (PD) and to determine correlations between their concentrations and severity of non-motor PD symptoms. Materials and methods. 67 patients at I–II PD stages and 20 healthy controls took part in the research. Cognitive functions were examined due to the Montreal Cognitive Assessment test – MoCA test. For the severity of psycho-emotional disorders evaluation the following scales and questionnaires were used: Night Sleep Assessment Questionnaire by A. M. Vein, Zung test for anxiety, apathy Starkstein scale, Boston stress-resistance test, Beck Depression Inventory (BDI-II). We performed ELISA test for determination of glutathione peroxidase (GPx) and glutathione-S-transferase (GST) activities and 3-nitrotyrosine (3-NT) level in blood plasma of participants (Elabscience® kit). Results. The middle age of PD patients and healthy controls was 64.35 ± 1.22 and 66.40 ± 0.70 years, respectively. GPx activity in plasma of patients at І–ІІ PD stages was significantly lower than in healthy controls (P < 0.001) and was higher at the I stage compared to the II PD stage (P = 0.003). Also GPx activity in PD patients with normal cognition was higher than in PD patients with cognitive impairment (P = 0.042). The GST activity in plasma of PD patients with anxiety was significantly lower (P = 0.002) compared to those without anxiety, and 3-NT blood plasma level in PD patients with moderate anxiety was higher than in those without one (P = 0.029). Conclusions. The activity of antioxidant GPx was significantly lower in PD patients at early stages compared to healthy controls, and in PD patients in the II stage of the disease compared to the I stage, and it was significantly lower in PD patients with cognitive impairment. PD patients with moderate anxiety had lower 3-NT levels and GST activity in blood plasma.

Download Full-text

Relationship S100 protein levels in blood plasma with a frequency of occurrence of cardiovascular complications in Parkinson's disease

Parkinsonism & Related Disorders ◽

10.1016/j.parkreldis.2015.10.081 ◽

2016 ◽

Vol 22 ◽

pp. e46

Author(s):

Mirzo Juraev ◽

Rustambek Matmurodov ◽

Khanifa Khalimova

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Blood Plasma ◽

S100 Protein ◽

Cardiovascular Complications ◽

Frequency Of Occurrence ◽

Protein Levels ◽

In Blood Plasma

Download Full-text

Neural network algorithm for the early detection of Parkinson's disease from blood plasma by FTIR micro-spectroscopy

Vibrational Spectroscopy ◽

10.1016/j.vibspec.2010.01.019 ◽

2010 ◽

Vol 53 (2) ◽

pp. 181-188 ◽

Cited By ~ 20

Author(s):

Shiek S.S.J. Ahmed ◽

Winkins Santosh ◽

Suresh Kumar ◽

T. Hema Thanka Christlet

Keyword(s):

Neural Network ◽

Parkinson’S Disease ◽

Parkinson's Disease ◽

Early Detection ◽

Blood Plasma ◽

Network Algorithm ◽

Neural Network Algorithm

Download Full-text

A blood marker for Parkinson’s Disease: Neuronal exosome-derived α-synuclein

10.21203/rs.3.rs-783910/v1 ◽

2021 ◽

Author(s):

Annika Kluge ◽

Josina Bunk ◽

Eva Schaeffer ◽

Alice Drobny ◽

Wei Xiang ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Blood Plasma ◽

Protein Misfolding ◽

Blood Test ◽

Plasma Samples ◽

Blood Biomarker ◽

Blood Marker ◽

Amplification Assay ◽

Β Sheet

Abstract To date, no reliable clinically applicable biomarker has been established for Parkinson’s disease (PD). Our results indicate that a long hoped blood test for Parkinson’s disease may be realized. We here assess the potential of pathological α-synuclein originating from neuron-derived exosomes from blood plasma as a possible biomarker. Following the isolation of neuron-derived exosomes from plasma of PD patients and non-PD individuals immunoblot analyses were performed to detect exosomal α-synuclein. Under native conditions significantly increased signals of disease-associated α-synuclein forms in neuron-derived exosomes were measured in all individuals with PD and clearly distinguished PD samples from controls. By performing a protein misfolding cyclic amplification assay these aggregates could be amplified and seeding could be demonstrated. Moreover, the aggregates exhibited β-sheet-rich structures and showed a fibrillary appearance. Our study demonstrates that the detection of pathological α-synuclein conformers from neuron-derived exosomes from plasma samples has the potential of a promising blood-biomarker of PD.

Download Full-text